IFEX PWS 2G/VIAL 2 G
IFOSFAMIDE : 2 G · DIN 00797235 · BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB
Health Canada status: CANCELLED POST MARKET
What is IFEX PWS 2G/VIAL?
IFEX PWS 2G/VIAL 2 G contains IFOSFAMIDE : 2 G. It is listed in the Health Canada Drug Product Database under DIN 00797235, held by BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 14-Aug-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00797235 |
|---|---|
| Brand name | IFEX PWS 2G/VIAL |
| Generic / active ingredient | IFOSFAMIDE : 2 G |
| Manufacturer | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB |
| Strength | 2 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01AA06 IFOSFAMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 14-Aug-1997 |
| Original market date | 1989-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code L01AA06 IFOSFAMIDE. 2 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IFEX | 1 G | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241357 |
| IFEX | 3 G | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241356 |
| IFEX PWS 1GM/VIAL | 1 G | POWDER FOR SOLUTION | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00797227 |
| IFEX PWS 3GM/VIAL | 3 G | POWDER FOR SOLUTION | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00808601 |
| IFOSFAMIDE FOR INJECTION | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | CANCELLED POST MARKET | DIN 02246565 |
| IFOSFAMIDE FOR INJECTION | 3 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | CANCELLED PRE MARKET | DIN 02246566 |
Who else supplies IFOSFAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IFOSFAMIDE appears in 15 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.